Although not fully understood, both GIP agonism and antagonism surprisingly benefit obesity-diabetes but neither approach is superior to the substantial benefits of recently introduced unimolecular peptides targeting both GIP and GLP-1 receptors. Here, GIP is linked to obesity disorder.